Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s
health innovation, today announced the appointment of Sophia N.
Ononye-Onyia, PhD MPH MBA to its Board of Directors.
“We are thrilled to add Dr. Ononye-Onyia to the
Daré Board,” said Sabrina Martucci Johnson, Daré’s President and
CEO. “Sophia has demonstrated the value of her leadership to global
biopharmaceutical companies throughout her career. Her experience
supporting commercialization of women's health products positions
her to provide strategic guidance as our product candidates advance
toward commercialization, and as we explore the variety of
go-to-market partnering strategies to enhance their value for our
shareholders.”
Dr. Ononye-Onyia is the founder and CEO of The
Sophia Consulting Firm, which provides strategic marketing and
communications consulting services to pharmaceutical, biotech and
health tech companies. Dr. Ononye-Onyia is also the creator, host
and producer of the Amplifying Scientific Innovation Video Podcast
which provides a platform for senior executives in the biotech and
pharmaceutical industries to share their perspectives on the
pharmaceutical industry on critical issues such as health equity,
inclusion and diversity. Previously, Dr. Ononye-Onyia served in a
variety of senior leadership roles including Executive Vice
President, Managing Director at Rx Medical Dynamics LLC where she
provided strategy consulting services related to commercial
preparedness for global biopharmaceutical companies across various
therapeutic areas including women’s health; Head of Corporate
Communications of OncoSec Medical Inc., a biotechnology company
focused on cytokine-based intratumoral cancer immunotherapies; and
Director of Healthcare & Life Sciences Practice of The Beacon
Group, a growth strategy consulting firm.
“I’m immensely honored and delighted to join the
Daré Board at a pivotal point in the Company’s trajectory as it
prepares to achieve several meaningful portfolio objectives
inclusive of the commerciazation of DARE-BV1,” said Dr. Sophia
Ononye-Onyia. “I look forward to utilizing my multidisciplinary
background, passion for scientific innovations and demonstrated
proficiency in global commercialization programs to advance Daré’s
leadership position in women’s health.”
Dr. Ononye-Onyia was recently selected to join
the inaugural class of the EY Entrepreneurs Access Network,
serves on the Advisory Council of the Dell Women's Entrepreneur
Network and is President of the New York Chapter Board of Directors
for the Healthcare Businesswomen’s Association. Dr. Ononye-Onyia
also serves as an Entrepreneur-in-Residence at the Yale University
Office of Cooperative Research. Dr. Ononye-Onyia received a PhD in
Medicinal Chemistry and MBA from the University of Connecticut, a
Master’s in Public Health from Bowling Green State University and
the University of Toledo, and a BS Honors in Chemistry, with a
specialization in Biochemistry, from Bowling Green State
University. Dr. Ononye-Onyia completed her postdoctoral
training in breast medical oncology research at the Yale School of
Medicine.
About Daré Bioscience
Daré Bioscience is a clinical-stage
biopharmaceutical company committed to the advancement of
innovative products for women’s health. The company’s mission is to
identify, develop and bring to market a diverse portfolio of
differentiated therapies that expand treatment options, improve
outcomes and facilitate convenience for women, primarily in the
areas of contraception, vaginal health, sexual health, and
fertility.
Daré’s product portfolio includes potential
first-in-category candidates in clinical development: Ovaprene®, a
novel, investigational hormone-free monthly intravaginal
contraceptive whose U.S. commercial rights are under a
license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream
formulation of sildenafil to treat female sexual arousal disorder
utilizing the active ingredient in Viagra®; DARE-BV1, a unique
hydrogel formulation of clindamycin phosphate 2% to treat bacterial
vaginosis via a single application; and DARE-HRT1, a combination
bio-identical estradiol and progesterone intravaginal ring for
hormone therapy following menopause. To learn more about Daré’s
full portfolio of women’s health product candidates, and mission to
deliver differentiated therapies for women, please
visit www.darebioscience.com.
Daré may announce material information about its
finances, product candidates, clinical trials and other matters
using the Investors section of its website
(http://ir.darebioscience.com), SEC filings, press releases, public
conference calls and webcasts. Daré will use these channels to
distribute material information about the company, and may also use
social media to communicate important information about the
company, its finances, product candidates, clinical trials and
other matters. The information Daré posts on its investor relations
website or through social media channels may be deemed to be
material information. Daré encourages investors, the media, and
others interested in the company to review the information Daré
posts in the Investors section of its website and to follow these
Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates
to the list of social media channels the company may use to
communicate information will be posted on the investor relations
page of Daré’s website mentioned above.
Forward-Looking Statements
Daré cautions you that all statements, other
than statements of historical facts, contained in this press
release, are forward-looking statements. Forward-looking
statements, in some cases, can be identified by terms such as
“believe,” “may,” “will,” “estimate,” “continue,” “anticipate,”
“design,” “intend,” “expect,” “could,” “plan,” “potential,”
“predict,” “seek,” “should,” “would,” “contemplate,” “project,”
“target,” “tend to,” or the negative version of these words and
similar expressions. In this press release, forward-looking
statements include, but are not limited to, statements relating to
potential commercial partnerships and their ability to enhance the
value of Daré’s product candidates. Forward-looking statements
involve known and unknown risks, uncertainties and other factors
that may cause Daré’s actual results, performance or achievements
to be materially different from future results, performance or
achievements expressed or implied by the forward-looking statements
in this press release, including, without limitation, risk and
uncertainties related to: Daré’s ability to raise additional
capital when and as needed to advance its product candidates and
continue as a going concern; the effects of the COVID-19 pandemic
on Daré’s operations, financial results and condition, and ability
to achieve current plans and objectives, including the potential
impact of the pandemic on Daré’s ability to timely enroll, conduct
and report results of its clinical trials and on the ability of
third parties on which Daré relies to assist in the conduct of its
business, including its clinical trials, to fulfill their
contractual obligations to Daré; Daré’s ability to develop, obtain
regulatory approval for, and commercialize its product candidates;
the failure or delay in starting, conducting and completing
clinical trials or obtaining FDA or foreign regulatory approval for
Daré’s product candidates in a timely manner; Daré’s ability to
design and conduct successful clinical trials, to enroll a
sufficient number of patients, to meet established clinical
endpoints, to avoid undesirable side effects and other safety
concerns, and to demonstrate sufficient safety and efficacy of its
product candidates; the risk that positive findings in early
clinical and/or nonclinical studies of a product candidate may not
be predictive of success in subsequent clinical and/or nonclinical
studies of that candidate; the risk that developments by
competitors make Daré’s product candidates less competitive or
obsolete; failure of Daré’s product candidates, if approved, to
gain market acceptance or obtain adequate coverage from third-party
payers; Daré’s ability to retain its licensed rights to develop and
commercialize a product candidate; Daré’s ability to satisfy the
monetary obligations and other requirements in connection with its
exclusive, in-license agreements covering the critical patents and
related intellectual property related to its product candidates;
the risks that the license agreement with Bayer may not become
effective and, if it becomes effective, that future payments to
Daré under the agreement may be significantly less than the
anticipated or potential amounts; developments by Daré’s
competitors that make its product candidates less competitive or
obsolete; Daré’s dependence on third parties to conduct clinical
trials and manufacture clinical trial material; Daré’s ability to
adequately protect or enforce its, or its licensor’s, intellectual
property rights; the lack of patent protection for the active
ingredients in certain of Daré’s product candidates which could
expose its products to competition from other formulations using
the same active ingredients; cyber attacks, security breaches or
similar events that compromise Daré’s technology systems or those
of third parties on which it relies and/or significantly disrupt
Daré’s business; and disputes or other developments concerning
Daré’s intellectual property rights. Daré’s forward-looking
statements are based upon its current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. All forward-looking statements are expressly qualified
in their entirety by these cautionary statements. For a detailed
description of Daré’s risks and uncertainties, you are encouraged
to review its documents filed with the SEC including Daré’s recent
filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not
to place undue reliance on forward-looking statements, which speak
only as of the date on which they were made. Daré undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made,
except as required by law.
Contact:
Investors on behalf of Daré Bioscience, Inc.:Tom
MastersonAllele Capital
Partnerstmasterson@allelecapital.com646.573.3216
Source: Daré Bioscience, Inc.
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Jul 2023 to Jul 2024